secwatch.observer — SEC 8-K summary
======================================

Issuer:     SOLENO THERAPEUTICS INC (SLNO)
CIK:        0001484565
Form:       8-K
Filed at:   2025-09-10T23:59:59+00:00
Accession:  0001193125-25-199882
Event type: regulatory
Sentiment:  negative
Materiality: 0.65
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

Soleno reports death of VYKAT XR patient; company says not drug-related
-----------------------------------------------------------------------

- A 17-year-old male with lymphedema, thrombophlebitis, and obesity died from pulmonary embolus; FAERS report filed.
- Treating physician and Soleno assessed the death as not related to VYKAT XR treatment.
- Soleno reaffirms VYKAT XR safety profile and urges use per FDA-approved label.
- Company will not comment on future adverse events unless directly linked to VYKAT XR and unexpected per label.
- Prader Willi Syndrome patients have reduced life expectancy; mean age of death is 29.5 years per 40-year study.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525199882/0001193125-25-199882-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1484565/000119312525199882/d88981d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-199882

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer